Ads
related to: what is factor x deficiency treatment for cancer patients
Search results
Results From The WOW.Com Content Network
Factor X deficiency (X as Roman numeral ten) is a bleeding disorder characterized by a lack in the production of factor X (FX), an enzyme protein that causes blood to clot in the coagulation cascade. Produced in the liver FX when activated cleaves prothrombin to generate thrombin in the intrinsic pathway of coagulation.
Inborn deficiency of factor X is very rare (1:1,000,000), and may present with epistaxis (nosebleeds), hemarthrosis (bleeding into joints) and gastrointestinal blood loss. . Apart from congenital deficiency, low factor X levels may occur occasionally in a number of disease stat
Once a cancer has metastasized, prognosis normally becomes much worse. About half of patients receiving treatment for invasive cancer (excluding carcinoma in situ and non-melanoma skin cancers) die from that cancer or its treatment. [25] A majority of cancer deaths are due to metastases of the primary tumor. [204]
Nutritional problems are also frequently seen in cancer patients at diagnosis and through chemotherapy treatment. Research suggests that in children and young people undergoing cancer treatment, parenteral nutrition may help with this leading to weight gain and increased calorie and protein intake, when compared to enteral nutrition.
Cancer patients undergo many obstacles and one of these includes mental strain. It is very common for cancer patients to become stressed, overwhelmed, uncertain, and even depressed. [46] The use of chemo is a very harsh treatment causing the cells of the body to die.
GATA2 deficiency is a grouping of several disorders caused by common defect, namely, familial or sporadic inactivating mutations in one of the two parental GATA2 genes. Because the gene is haploinsufficient, mutations that cause a reduction in cellular levels of the gene's product, GATA2, are autosomal dominant.
The treatment may mirror that of chemotherapy-induced myelosuppression or may be to change to an alternate drug or to temporarily suspend treatment. Because the bone marrow is the manufacturing center of blood cells, the suppression of bone marrow activity causes a deficiency of blood cells.
The protein that is encoded by this gene inhibits the NF-κB transcription factor through the masking of nuclear localization signals from NF-κB transcription factor proteins, this process keeps them in an inactive state in the cytoplasm. It also helps blocking the NF-κB transcription factors protein's ability of binding itself to DNA. The ...